AAPL   323.34 (+0.46%)
FB   232.72 (+0.35%)
AMZN   2,472.41 (+0.06%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
FB   232.72 (+0.35%)
AMZN   2,472.41 (+0.06%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
FB   232.72 (+0.35%)
AMZN   2,472.41 (+0.06%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
FB   232.72 (+0.35%)
AMZN   2,472.41 (+0.06%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

NASDAQ:REPLReplimune Group Stock Price, Forecast & News

$19.96
+0.20 (+1.01 %)
(As of 06/2/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.67
Now: $19.96
$20.26
50-Day Range
$10.71
MA: $16.43
$21.22
52-Week Range
$8.58
Now: $19.96
$22.13
Volume190,463 shs
Average Volume104,675 shs
Market Capitalization$731.45 million
P/E RatioN/A
Dividend YieldN/A
Beta3.33
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More
Replimune Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPL
CUSIPN/A
CIKN/A
Phone781-222-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.36 per share

Profitability

Net Income$-30,830,000.00

Miscellaneous

Employees62
Market Cap$731.45 million
Next Earnings Date6/26/2020 (Estimated)
OptionableNot Optionable

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

Replimune Group (NASDAQ:REPL) Frequently Asked Questions

How has Replimune Group's stock been impacted by COVID-19 (Coronavirus)?

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, REPL stock has increased by 67.6% and is now trading at $20.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Replimune Group?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Replimune Group.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, June 26th 2020. View our earnings forecast for Replimune Group.

How were Replimune Group's earnings last quarter?

Replimune Group Inc (NASDAQ:REPL) issued its quarterly earnings data on Thursday, February, 13th. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.10. View Replimune Group's earnings history.

What price target have analysts set for REPL?

6 Wall Street analysts have issued twelve-month price targets for Replimune Group's stock. Their forecasts range from $12.50 to $30.00. On average, they expect Replimune Group's stock price to reach $23.58 in the next year. This suggests a possible upside of 17.9% from the stock's current price. View analysts' price targets for Replimune Group.

Has Replimune Group been receiving favorable news coverage?

News headlines about REPL stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Replimune Group earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutReplimune Group.

Who are some of Replimune Group's key competitors?

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Peabody Energy (BTUUQ), Myovant Sciences (MYOV), Pfizer (PFE), Fate Therapeutics (FATE), Immunomedics (IMMU), AbbVie (ABBV), Aerie Pharmaceuticals (AERI), Axsome Therapeutics (AXSM) and Cleveland-Cliffs (CLF).

Who are Replimune Group's key executives?

Replimune Group's management team includes the following people:
  • Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)
  • Dr. Robert Coffin, Pres, CEO & Director (Age 54)
  • Dr. Colin Love, Chief Operating Officer (Age 61)
  • Dr. Pamela Esposito, Chief Bus. Officer (Age 45)
  • Stephen Gorgol, Chief Accounting Officer

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (8.13%), BlackRock Inc. (2.84%), Emerald Advisers LLC (2.17%), Emerald Mutual Fund Advisers Trust (2.13%), Victory Capital Management Inc. (1.22%) and Victory Capital Management Inc. (1.22%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, Joseph P Slattery, Philip Astley-Sparke and Robert Coffin. View institutional ownership trends for Replimune Group.

Which major investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Squarepoint Ops LLC, Morgan Stanley, Wells Fargo & Company MN, Emerald Mutual Fund Advisers Trust, Alps Advisors Inc., and Deutsche Bank AG. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Philip Astley-Sparke, and Robert Coffin. View insider buying and selling activity for Replimune Group.

Which major investors are buying Replimune Group stock?

REPL stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Nuveen Asset Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., Ensign Peak Advisors Inc, AQR Capital Management LLC, and UBS Group AG. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega, Fund Iv LP Omega, Jason P Rhodes, and Joseph P Slattery. View insider buying and selling activity for Replimune Group.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $20.00.

How big of a company is Replimune Group?

Replimune Group has a market capitalization of $733 million. The company earns $-30,830,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Replimune Group employs 62 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is www.replimune.com.

How can I contact Replimune Group?

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.